Investigational Drugs Central Nervous System

CentralNervous System Drug News

Central Nervous System Jobs

Find an open position today!

Repligen reaches Phase IIb with Uridine

Repligen launches clinical phase 2b for bipolar depressive syndromes on 150 patients. by Caroline A. Falciola, PhD , 07/11/2008

Targeting MS at the root - vaccine developments

Currently approved MS treatments are not very efficient on the disease's relapses, but many new peptide-based vaccines are being clinically tested and show very promising results by Caroline A. Falciola, PhD , 27/10/2008

Jazz Pharmaceuticals still in the race to treat Fibromyalgia syndrome

The final patient has completed participation in the first Phase III pivotal clinical trial of JZP-6 for the treatment of fibromyalgia.15/09/2008

Valeant and GSK sign collaboration deal worth up to $820 million

GSK obtains the exclusive worldwide development and commercialisation rights to Valeant Pharmaceuticals' epilepsy drugs.01/09/2008

Intensive Research to Treat MS

Due to unmet medical need and market potential, intensive research is underway to develop therapies against MS.06/08/2008

Alzheimer's treatment closer to market.

Elan and Wyeth announced positive results for phase II clinical trials of bapineuzumab designed to treat Alzheimer's disease.22/07/2008




CentralNervous SystemPress releases

SelectedCentral Nervous System drugs.
SUMATRIPTAN (?)Sumatriptan is indicated for the treatment of migraine attacks with or without aura in adults. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation
SUMATRIPTAN (?)Sumatriptan is indicated for the treatment of migraine attacks with or without aura in adults. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation
SUMATRIPTAN (?)Sumatriptan is indicated for the treatment of migraine attacks with or without aura in adults. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation